Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
IF: 2.9 5-Year IF: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Print: 0743-4863
ISSN Online: 2162-660X

Volumes:
Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2013005268
pages 183-216

Psoriasis Clinical Implications and Treatment: A Review

Ashlesha S. Raut
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Nathalal Parekh Marg, Matunga, Mumbai 400 019, India
Rashmi H. Prabhu
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Nathalal Parekh Marg, Matunga, Mumbai 400 019, India
Vandana B. Patravale
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Nathalal Parekh Marg, Matunga, Mumbai, Maharashtra, India

ABSTRACT

Psoriasis is a common skin disorder affecting the population worldwide. It is a T-cell mediated autoimmune disorder leading to keratinocyte hyperproliferation. Psoriasis has genetic predisposition that is further aggravated by certain stimulating factors. In spite of significant advances in understanding the pathogenesis of psoriasis, the exact etiology of the disease remains unknown. The clinical manifestations of this disease include various forms that affect different parts of the body. Treatment options vary according to the mode of application or severity of the disease. Earlier treatments have included application of emollients or keratolytic agents to hydrate the skin or shed off the skin. But later treatments have been modified to treat the underlying T-cell proliferation. Hence, topical treatments like coal tar, vitamin D, retinoids, topical calcineurin inhibitors for treating mild psoriasis, systemic treatments including methotrexate, cyclosporine, acitretin, hydroxyurea, as well as light therapy for severe psoriasis have become more prominent. Current treatment modalities are associated with the risk of serious side effects from prolonged treatment. Combinations of these therapies have provided effective and rapid modalities to suppress the disease and reduce the side effects of treatment. In addition, newer carrier systems for conventional drugs are being developed to improve the effectiveness of treatment and reduce the side effects. Development of biologics and gene therapy have revolutionized the treatment of this skin disease. Although an array of therapies to suppress the psoriatic condition exists, none are curative.


Articles with similar content:

Options and Opportunities for Clinical Management and Treatment of Psoriasis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 1
Udita Agrawal, Devyani Dube, Madhu Gupta, Suresh P. Vyas
A Review of Hyperthermia Combined With Radiotherapy/Chemotherapy on Malignant Tumors
Critical Reviews™ in Biomedical Engineering, Vol.38, 2010, issue 1
Wei Rao, Zhong-Shan Deng
Oral Squamous Cell Carcinoma: Current Treatment Strategies and Nanotechnology-Based Approaches for Prevention and Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.33, 2016, issue 4
Munira Momin, Chintan Bhavsar, Sankalp A. Gharat
Biomarkers of DNA Repair and Related Pathways: Significance of Treatment in Triple-Negative Breast Cancer
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 5-6
Wenwen Guo, Xue He, Congyang Wang, Nannan Chen, Yan Wang, Fengxia He, Li Lin
The Potential of Liposomes in Oral Drug Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.15, 1998, issue 5
Keith E. Anderson, James A. Rogers